ALQAEM to release online blood sugar monitor in the M CialisPrix.Net .E.N.A. Regions The Health Treatment Division of ALQAEM International FZE, the exclusive master distributor for the M.E.N.A. Area of the UFIT noninvasive medical device created by Biosign Systems Inc. Of Canada, is certainly pleased to announce that it provides placed orders for delivery this quarter and will begin a limited discharge in March to those M.E.N.A. Areas that recognize the CE Mark for medical device sign up. ALQAEM and Biosign jointly announced the very successful public debut of the UFIT Heath Monitoring System at Arab Health 2011 in Dubai, UAE , where for the very first time, the features and great things about the UFIT10-20 noninvasive blood circulation pressure and blood glucose monitor were demonstrated to the general public locally in the Gulf Area. The device will take the pulse at the wrist through an inflatable cuff and immediately produces pulse trace, blood blood and pressure glucose measurement outcomes. UFIT TEN-20 will not require any kind of bloodstream sampling or under-pores and skin implant. All measurements are indirect, noninvasive, and passive and don’t produce any hazardous waste. The total results are stored on Biosign servers along with the digital test sample. UFIT TEN-20 is authorized under ISO 13485 for the noninvasive measurement of blood circulation pressure and blood glucose, and bears the CE Tag. John Rizvi, Handling Director of ALQAEM mentioned: At Arab Wellness 2011 we received a lot of interest from key government leaders and retail partners from UAE, Saudi Arabia, Egypt and several additional M.E.N.A. Countries. We will today launch this remarkable system to scientific and institutional clients, which will tend to maximize the efficiency of every UFITPAD unit, and generate extra goodwill and media attention for both ALQAEM and Biosign. Related StoriesApoE4-carrying males with Alzheimer's disease vulnerable to brain bleedsDiscovery can offer clues to how some infections control expression of genetic materialCHOP researchers delay symptoms, extend lifespan in animal style of Batten diseaseALS is a fatal and progressive, neurodegenerative disorder affecting the electric motor neurons in the central anxious system. This network marketing leads to lack of voluntary muscle movement, paralysis and finally death from respiratory failure. The reason for most cases of ALS is not known. Approximately 10 % of instances are inherited. In 1993, a team of researchers led by Dr. Brown discovered the 1st gene associated with familial ALS, a proteins anti-oxidant referred to as superoxide dismutase, or SOD1. As part of this collaboration, RXi will provide its next generation RNAi materials and technology to Dr. Dr. RXi has a long standing interest in ALS and we hope that this collaboration will enable the evaluation of the medical potential of the sd-rxRNA technology system for the treatment of ALS and other diseases of the central nervous system.”.